Insider trading · Q3 2026 · CIK 1563665

Harvard Apparatus Regenerative Technology, Inc. (HRGN) insider trading.

In Q3 2026, insiders at Harvard Apparatus Regenerative Technology, Inc. reported 3 non-derivative transactions on 2 Forms 3, 4 and 5: 2 open-market purchases worth $394K and 0 sales.

Transactions
3
Purchases (P)
2
Sales (S)
0
Net shares, P minus S
368,630
Insiders
1
Last filed
2026-09-25

Insiders

InsiderRelationshipTransactionsBuysSales
He JunliDirector, Officer · CEO320

Transactions

3 non-derivative rows, newest transaction first. Shares and prices as filed.
DateInsiderCodeSharesPriceOwned afterFiling
2026-09-15He JunliP (A)6,725$2.151,332,930Form 4
2026-09-11He JunliP (A)361,905$1.051,326,205Form 4
2026-09-11He JunliC (A)683,725$1.05964,300Form 4

Transaction codes in this quarter

Get HRGN insider transactions through the API

Request with your API key
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1563665&limit=100" \
  -H "Authorization: Bearer $SEC_API_KEY"

Insider trading API guide · HRGN company page · Harvard Apparatus Regenerative Technology, Inc. on SEC.gov

Questions

Are insiders buying or selling Harvard Apparatus Regenerative Technology, Inc. (HRGN)?

In Q3 2026, insiders at Harvard Apparatus Regenerative Technology, Inc. reported 3 non-derivative transactions on 2 Forms 3, 4 and 5: 2 open-market purchases worth $394K and 0 sales. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.

Where do these Harvard Apparatus Regenerative Technology, Inc. insider trades come from?

From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.

Source: SEC Insider Transactions Data Sets, Q3 2026, retrieved 2026-10-27. Footnotes, derivative holdings and amendments are in the linked filings. Not investment advice.

Plain-text version for agents and LLMs: /insider-trading/hrgn.md

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.